Management of immune checkpoint inhibitor‐related dermatologic adverse events

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. The unique spectrum of immune‐related adverse events (IrAEs) may occur during treatment. Dermatologic toxicities appear to be one of the most prevalent immunotherapy‐related adverse events. The most common symptoms are maculop...

Descripción completa

Detalles Bibliográficos
Autores principales: Si, Xiaoyan, He, Chunxia, Zhang, Li, Liu, Xiaowei, Li, Yue, Wang, Hanping, Guo, Xiaoxiao, Zhou, Jiaxin, Duan, Lian, Wang, Mengzhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Clinical Guideline
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997012/
https://www.ncbi.nlm.nih.gov/pubmed/31814310
http://dx.doi.org/10.1111/1759-7714.13275
_version_ 1783493608165343232
author Si, Xiaoyan
He, Chunxia
Zhang, Li
Liu, Xiaowei
Li, Yue
Wang, Hanping
Guo, Xiaoxiao
Zhou, Jiaxin
Duan, Lian
Wang, Mengzhao
Zhang, Li
author_facet Si, Xiaoyan
He, Chunxia
Zhang, Li
Liu, Xiaowei
Li, Yue
Wang, Hanping
Guo, Xiaoxiao
Zhou, Jiaxin
Duan, Lian
Wang, Mengzhao
Zhang, Li
author_sort Si, Xiaoyan
collection PubMed
description Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. The unique spectrum of immune‐related adverse events (IrAEs) may occur during treatment. Dermatologic toxicities appear to be one of the most prevalent immunotherapy‐related adverse events. The most common symptoms are maculopapular rash and pruritus. Serious dermatologic toxicities including Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reactions with eosinophilia and systemic symptoms are rare. In this review, we summarize guidelines of management of immunotherapy‐related toxicities, case reports, and proposed treatment recommendation.
format Online
Article
Text
id pubmed-6997012
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-69970122020-02-05 Management of immune checkpoint inhibitor‐related dermatologic adverse events Si, Xiaoyan He, Chunxia Zhang, Li Liu, Xiaowei Li, Yue Wang, Hanping Guo, Xiaoxiao Zhou, Jiaxin Duan, Lian Wang, Mengzhao Zhang, Li Thorac Cancer Clinical Guideline Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. The unique spectrum of immune‐related adverse events (IrAEs) may occur during treatment. Dermatologic toxicities appear to be one of the most prevalent immunotherapy‐related adverse events. The most common symptoms are maculopapular rash and pruritus. Serious dermatologic toxicities including Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reactions with eosinophilia and systemic symptoms are rare. In this review, we summarize guidelines of management of immunotherapy‐related toxicities, case reports, and proposed treatment recommendation. John Wiley & Sons Australia, Ltd 2019-12-09 2020-02 /pmc/articles/PMC6997012/ /pubmed/31814310 http://dx.doi.org/10.1111/1759-7714.13275 Text en © 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Guideline
Si, Xiaoyan
He, Chunxia
Zhang, Li
Liu, Xiaowei
Li, Yue
Wang, Hanping
Guo, Xiaoxiao
Zhou, Jiaxin
Duan, Lian
Wang, Mengzhao
Zhang, Li
Management of immune checkpoint inhibitor‐related dermatologic adverse events
title Management of immune checkpoint inhibitor‐related dermatologic adverse events
title_full Management of immune checkpoint inhibitor‐related dermatologic adverse events
title_fullStr Management of immune checkpoint inhibitor‐related dermatologic adverse events
title_full_unstemmed Management of immune checkpoint inhibitor‐related dermatologic adverse events
title_short Management of immune checkpoint inhibitor‐related dermatologic adverse events
title_sort management of immune checkpoint inhibitor‐related dermatologic adverse events
topic Clinical Guideline
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997012/
https://www.ncbi.nlm.nih.gov/pubmed/31814310
http://dx.doi.org/10.1111/1759-7714.13275
work_keys_str_mv AT sixiaoyan managementofimmunecheckpointinhibitorrelateddermatologicadverseevents
AT hechunxia managementofimmunecheckpointinhibitorrelateddermatologicadverseevents
AT zhangli managementofimmunecheckpointinhibitorrelateddermatologicadverseevents
AT liuxiaowei managementofimmunecheckpointinhibitorrelateddermatologicadverseevents
AT liyue managementofimmunecheckpointinhibitorrelateddermatologicadverseevents
AT wanghanping managementofimmunecheckpointinhibitorrelateddermatologicadverseevents
AT guoxiaoxiao managementofimmunecheckpointinhibitorrelateddermatologicadverseevents
AT zhoujiaxin managementofimmunecheckpointinhibitorrelateddermatologicadverseevents
AT duanlian managementofimmunecheckpointinhibitorrelateddermatologicadverseevents
AT wangmengzhao managementofimmunecheckpointinhibitorrelateddermatologicadverseevents
AT zhangli managementofimmunecheckpointinhibitorrelateddermatologicadverseevents

Ejemplares similares